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Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery 
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*
Butler University College of Pharmacy and Health Sciences, Indianapolis, Indiana; 
†
Riley Hospital for Children at 
Indiana University Health, Department of Pharmacy, Indianapolis, Indiana.  
ABSTRACT 
Background: Vancomycin and oxacillin may be used together as empiric coverage in patients 
with proven or suspected Staphylococcus aureus infections. Though vancomycin hydrochloride 
20 mg/mL and oxacillin sodium 160 mg/mL are reported to be compatible via Y-site delivery, Y-
site compatibility of commonly used concentrations, vancomycin 10 mg/mL and oxacillin 20 
mg/mL, has not yet been reported. Objective: To determine the Y-site compatibility of 
vancomycin 10 mg/mL and oxacillin 20 mg/mL. Methods: One vancomycin hydrochloride 1 g 
vial was reconstituted with 10 mL sterile water for injection (SWFI) and diluted with 90 mL 5% 
dextrose in water (D5W) in an evacuated intravenous (IV) bag. One oxacillin sodium 2 g vial 
was reconstituted with 11.5 mL sterile water for injection and diluted with 88 mL sterile water 
for injection in an evacuated IV bag. Three mL of each vancomycin and oxacillin were mixed in 
4 test tubes to simulate Y-site delivery. Spectrometry, pH evaluation, and visual examination 
were performed for each test tube immediately following mixing and at 30 minutes, 1 hour, and 
2 hours after mixing. Results: Upon visual examination with multiple backgrounds, a white 
precipitant was immediately evident in the test tubes with vancomycin and oxacillin combined. 
Spectrometry results strongly supported evidence of precipitation throughout the duration of the 
experiment. Conclusions: Vancomycin 10 mg/mL and oxacillin 20 mg/mL were determined to 
be physically incompatible for Y-site delivery in this study, despite prior evidence that the 2 
medications in different concentrations were suitable for Y-site co-administration. 
 
 
Vancomycin is frequently used in addition to a beta-lactam antimicrobial agent such as oxacillin 
in the empiric treatment of suspected or proven Staphylococcus aureus infections, including 
bacteremia, endocarditis, and bone and joint infections. Reduced morbidity and mortality in 
patients with Staphylococcal bacteremia has been suggested when combination therapy of 
vancomycin and an antistaphylococcal β-lactam such as oxacillin, nafcillin, or cefazolin are 
empirically initiated when compared to vancomycin monotherapy.1 This regimen could be de-
escalated based on susceptibility data indicating methicillin-susceptible Staphylococcal species.2 
An in vitro study has demonstrated synergy of vancomycin and oxacillin for select vancomycin-
intermediate S. aureus (VISA) strains, suggesting that this combination may be of some use in 
those infections.2 
 
Oxacillin and nafcillin are beta-lactam antibiotics, and efficacy is dependent upon sustained drug 
concentrations. Dose optimization is often achieved by administration via continuous infusion. 
As pediatric patients may frequently have only one intravenous (IV) access site through which to 
receive IV medications, compatibility of IV solutions is particularly important when dosing 
frequencies and infusion strategies are considered. At Riley Hospital for Children, continuous 
infusions of nafcillin and oxacillin are common in combination with intermittent vancomycin 
infusions. Nafcillin 10 mg/mL has been demonstrated to be incompatible with vancomycin 2 to 
20 mg/mL, so the 2 drugs at the standard concentrations used at Riley Hospital for Children may 
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not be co-infused.3 A prior study determined that vancomycin 20 mg/mL and oxacillin 160 
mg/mL were physically compatible, but no published studies have assessed Y-site compatibility 
of vancomycin 10 mg/mL and oxacillin 20 mg/mL.4 The information from the previous study 
has been used at Riley Hospital for Children to infer compatibility of the lower concentrations, 
but recent experience has brought their compatibility into question. The objective of this study 
was to determine the Y-site compatibility of vancomycin and oxacillin at concentrations used at 
Riley Hospital for Children. 
 
METHODS 
The HEPA-filtered laboratory hood was turned on 30 minutes prior to starting the study. 
Vancomycin 10 mg/mL and oxacillin 20 mg/mL stock bags were prepared according to the 
institutional standards at Riley Hospital for Children. One vancomycin hydrochloride 1 g vial 
(Hospira, lot # 44455DD) was reconstituted with 10 mL sterile water for injection (SWFI) 
(Hospira) and diluted with 90 mL 5% dextrose in water (D5W) (Baxter) in an empty 150 mL 
Intravia container (Baxter). One oxacillin sodium 2 g vial (Auromedics, lot # 0C0214034) was 
reconstituted with 11.5 mL SWFI (Hospira) and diluted with 88 mL SWFI (Hospira) in an empty 
150 mL Intravia container (Baxter). Each bag was labeled and given a 24-hour expiration date 
once the bag spike was inserted. According to manufacturer-provided information, oxacillin in 
SWFI is stable for 4 days at room temperature and vancomycin in D5W is stable for 24 hours at 
room temperature.5,6  
 
A Spectronic 20D+ (Thermo Fisher Scientific, Waltham, MA) was used to measure absorbance. 
It was set to a wavelength of 700 nm and calibrated with deionized water to an absorbance of 
0.000. Absorbance of greater than 0.01 was considered evidence of turbidity. The pH meter 
(Oakton Instruments, Vernon Hills, IL) was calibrated with control solutions at pH of 7 and 4. 
Three mL of each vancomycin (10 mg/mL) and oxacillin (20 mg/mL) solutions were mixed in 4 
test tubes to simulate Y-site delivery. Six mL of each deionized water, D5W, SWFI, 
vancomycin, and oxacillin were added to separate test tubes for use as control solutions. 
Spectrometry, pH, and visual examination were performed for each test tube immediately 
following initial mixing (time 0) and 30 minutes, 1 hour, and 2 hours after mixing. Visual 
examination was performed for each control and mixture solution with an unaided eye on a white 
background, unaided eye on a black background, with a 4-cell Maglite on a white background, 
with a 4-cell Maglite on a black background, through a 4.0 diopter magnifying glass on a white 
background, and through a 4.0 diopter magnifying glass on a black background. 
 
RESULTS 
White precipitant was immediately present in the test tubes when the vancomycin and oxacillin 
solutions were combined (Table 1). The particulate matter was readily visualized with the 
unaided eye; therefore, results were unchanged upon examination with the magnifying glass or 
Maglite. Samples ranged from milky solutions to layered solutions with solid flakes of 
precipitant. Over the 2 hours of visual observation, some of the tubes had white precipitant settle 
to the bottom of the tube. No visual changes presented in any of the control solutions. 
Spectrometry results strongly supported evidence of precipitation in each of the vancomycin and 
oxacillin mixtures (Table 2). All mixture test tubes demonstrated absorbance greater than 0.01 
during each spectrometry reading, providing evidence of turbidity and particulate matter. During 
14 of 16 spectrometry testing points, absorbance was 1.999; the other 2 were 1.85 and 1.9. No 
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control solution reached absorbance of greater than 0.01 at any point during the study. The pH 
measurement of each sample was stable throughout the 2-hour observation period (Table 2). The 
oxacillin control sample had a mean pH of 7.6 (range, 7.4-7.9) while the vancomycin control 
sample had a mean pH of 3.125 (range, 3.1-3.2). When mixed, the vancomycin and oxacillin 
samples had a mean pH of 6.6 (range, 6.4-6.8). 
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DISCUSSION 
Vancomycin 10 mg/mL and oxacillin 20 mg/mL were determined to be physically incompatible 
for Y-site delivery in this study, despite prior evidence that the 2 medications in other 
concentrations were suitable for Y-site co-administration. Trissel used different concentrations of 
each drug (vancomycin hydrochloride 20 mg/mL and oxacillin sodium 160 mg/mL) but used the 
same diluents as this study and demonstrated compatibility.4 Our result was surprising given the 
compatibility of the mixture when higher concentrations were used and the demonstration of 
concentration-dependent compatibility of vancomycin and beta-lactam antibiotics found by 
Trissel and colleagues.3 Different manufacturers of vancomycin and oxacillin were used in 
Trissel’s study (Abbott Laboratories and Apothecon, respectively) than in our study, so 
differences in compatibility could be a result of inactive ingredients present in the different 
formulations.  
 
Chemical differences between vancomycin hydrochloride, oxacillin sodium, and their respective 
diluents may also explain the precipitation when these 2 drugs are mixed. The precipitant may be 
a result of acid-base reactions due to vancomycin being a hydrochloride salt (average pH 3.125) 
whereas oxacillin is a sodium salt (average pH 7.6).7 By increasing the pH when the 2 drugs 
were mixed, the hydrochloride salt may cause vancomycin to precipitate out of the solution. By 
mixing oxacillin sodium (average pH 7.6) in the D5W in which the vancomycin is diluted, the 
pH may become too low for oxacillin to remain in solution. 
 
Presence of a precipitant in this study indicates that vancomycin 10 mg/mL and oxacillin 20 mg/ 
mL should not be co-administered via Y-site. Due to inconsistency with prior studies, knowledge 
of this drug-drug incompatibility may prevent adverse events from occurring in future patients 
who are being empirically treated with this combination of antibiotics. Unfortunately, this may 
prevent patients with only one IV access point from empirically receiving a continuous infusion 
of oxacillin. 
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